Effect of Vitamin D Supplementation on Erythropoietin Dosage in Hemodialysis Patients Who Have Vitamin D Deficiency

Sponsor
Kaiser Permanente (Other)
Overall Status
Withdrawn
CT.gov ID
NCT00915317
Collaborator
(none)
0
1
5
0

Study Details

Study Description

Brief Summary

While vitamin D supplementation is safe and effective in repleting vitamin D levels in dialysis patients, the impact on anemia is unknown. The majority of hemodialysis patients require erythropoietin supplementation to maintain their serum hemoglobin between 11 and 12 gm/dL, a drug that is both costly and associated with significant side effects. If repletion of vitamin D significantly decreases erythropoietin requirements in hemodialysis patients, it would result in a substantial reduction in patient care costs. Our aim is to study the impact of ergocalciferol supplementation in hemodialysis patients with 25-hydroxyvitamin D deficiency. The investigators anticipate approximately 30% reduction in erythropoietin dose requirement in our hemodialysis population.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    0 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Effect of Vitamin D Supplementation on Erythropoietin Dosage in Hemodialysis Patients Who Have Vitamin D Deficiency
    Study Start Date :
    Oct 1, 2008
    Actual Primary Completion Date :
    Mar 1, 2009
    Actual Study Completion Date :
    Mar 1, 2009

    Outcome Measures

    Primary Outcome Measures

    1. erythropoietin dosage [6 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All hemodialysis patients at the Kaiser Permanente Los Angeles Medical Center with vitamin D deficiency [defined by 25-hydroxyvitamin D level less than 30 ng/ml]
    Exclusion Criteria:
    • Non-renal causes of anemia (myelodysplastic syndrome, multiple myeloma, pure red cell aplasia, thallassemia, and sickle cell anemia)

    • Active cancer

    • AIDS

    • refused erythropoeitin, intravenous iron or vitamin D analogs in the past

    • no erythropoeitin requirement for greater than 6 weeks

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kaiser Permanente Southern California Los Angeles California United States 90027

    Sponsors and Collaborators

    • Kaiser Permanente

    Investigators

    • Principal Investigator: Phillip S Yang, MD, Kaiser Permanente

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Kaiser Permanente
    ClinicalTrials.gov Identifier:
    NCT00915317
    Other Study ID Numbers:
    • 5125
    First Posted:
    Jun 8, 2009
    Last Update Posted:
    Mar 11, 2015
    Last Verified:
    Mar 1, 2015
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 11, 2015